Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 12/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021308 | 0.87 | ABL1 (0.41) | ABL1CREBBPKDM4EALDH1A1CYP1A2 | |
| SCHEMBL2389800 | 0.84 | KDM4E (0.38) | CFTRKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL2388560 | 0.80 | KDM4E (0.41) | CFTRKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL5168756 | 0.79 | KDM4E (0.41) | KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL13500111 | 0.78 | KDM4E (0.39) | CFTRKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL2389702 | 0.75 | CFTR (0.64) | ABL1KDRCFTRPDK2CREBBP | |
| SCHEMBL5167578 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL5167582 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL2388475 | 0.72 | KDM4E (0.41) | CFTRKDM4EALDH1A1CYP1A2HPGD | |
| SCHEMBL2392190 | 0.70 | HTR2A (0.45) | KDM4EALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| EP-1871749-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | ABL1 13/4885KDR 2478/4885CFTR 1356/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | ABL1 3495/4885KDR 3623/4885CFTR 1840/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | ABL1 38/4885KDR 2237/4885CFTR 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.